Condition: HPV-Related Squamous Cell Carcinoma · Sponsor: Hookipa Biotech GmbH
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| O'Neal Comprehensive Cancer Center at UAB | Birmingham, Alabama, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office | Fayetteville, Arkansas, United States | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| UCLA (University of California, Los Angeles) | Los Angeles, California, United States | — |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Loyola University Medical School | Maywood, Illinois, United States | — |
| University of Iowa Hospitals & Clinics | Iowa City, Iowa, United States | — |
| University of Kansas Medical Center | Fairway, Kansas, United States | — |
| Henry Ford Hospital | Detroit, Michigan, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04180215